학술논문
Outcomes of Cerebral Venous Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase
Document Type
Academic Journal
Author
van de Munckhof, Anita; Lindgren, Erik; Kleinig, Timothy J.; Field, Thalia S.; Cordonnier, Charlotte; Krzywicka, Katarzyna; Poli, Sven; Sánchez van Kammen, Mayte; Borhani-Haghighi, Afshin; Lemmens, Robin; Scutelnic, Adrian; Ciccone, Alfonso; Gattringer, Thomas; Wittstock, Matthias; Dizonno, Vanessa; Devroye, Annemie; Elkady, Ahmed; Günther, Albrecht; Cervera, Alvaro; Mengel, Annerose; Chew, Beng Lim Alvin; Buck, Brian; Zanferrari, Carla; Garcia-Esperon, Carlos; Jacobi, Christian; Soriano, Cristina; Michalski, Dominik; Zamani, Zohreh; Blacquiere, Dylan; Johansson, Elias; Cuadrado-Godia, Elisa; Vuillier, Fabrice; Bode, Felix J.; Caparros, François; Maier, Frank; Tsivgoulis, Georgios; Katzberg, Hans D.; Duan, Jiangang; Burrow, Jim; Pelz, Johann; Mbroh, Joshua; Oen, Joyce; Schouten, Judith; Zimmermann, Julian; Ng, Karl; Garambois, Katia; Petruzzellis, Marco; Carvalho Dias, Mariana; Ghiasian, Masoud; Romoli, Michele; Miranda, Miguel; Wronski, Miriam; Skjelland, Mona; Almasi-Dooghaee, Mostafa; Cuisenier, Pauline; Murphy, Seán; Timsit, Serge; Coutts, Shelagh B.; Schönenberger, Silvia; Nagel, Simon; Hiltunen, Sini; Chatterton, Sophie; Cox, Thomas; Bartsch, Thorsten; Shaygannejad, Vahid; Mirzaasgari, Zahra; Middeldorp, Saskia; Levi, Marcel M.; Kremer Hovinga, Johanna A.; Jood, Katarina; Tatlisumak, Turgut; Putaala, Jukka; Heldner, Mirjam R.; Arnold, Marcel; Aguiar de Sousa, Diana; Ferro, José M.; Coutinho, Jonathan M.
Source
Stroke. Oct 01, 2022 53(10):3206-3210
Subject
Language
English
ISSN
0039-2499
Abstract
BACKGROUND:: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. METHODS:: We used data from an international registry of patients who developed CVT within 28 days of SARS-CoV-2 vaccination, collected until February 10, 2022. VITT diagnosis was classified based on the Pavord criteria. Outcomes were mortality, functional independence (modified Rankin Scale score 0–2), VITT relapse, new thrombosis, and bleeding events (all after discharge from initial hospitalization). RESULTS:: Of 107 CVT-VITT cases, 43 (40%) died during initial hospitalization. Of the remaining 64 patients, follow-up data were available for 60 (94%) patients (37 definite VITT, 9 probable VITT, and 14 possible VITT). Median age was 40 years and 45/60 (75%) patients were women. Median follow-up time was 150 days (interquartile range, 94–194). Two patients died during follow-up (3% [95% CI, 1%–11%). Functional independence was achieved by 53/60 (88% [95% CI, 78%–94%]) patients. No new venous or arterial thrombotic events were reported. One patient developed a major bleeding during follow-up (fatal intracerebral bleed). CONCLUSIONS:: In contrast to the high mortality of CVT-VITT in the acute phase, mortality among patients who survived the initial hospitalization was low, new thrombotic events did not occur, and bleeding events were rare. Approximately 9 out of 10 CVT-VITT patients who survived the acute phase were functionally independent at follow-up.